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Diphtheria incidence has decreased in Europe since 
its resurgence in the 1990s, but circulation continues in 
some countries in eastern Europe, and sporadic cases 
have been reported elsewhere. Surveillance data from 
Diphtheria Surveillance Network countries and the World 
Health Organization European Region for 2000–2009 were 
analyzed. Latvia reported the highest annual incidence in 
Europe each year, but the Russian Federation and Ukraine 
accounted for 83% of all cases. Over the past 10 years, 
diphtheria incidence has decreased by >95% across the 
region. Although most deaths occurred in disease-endemic 
countries, case-fatality rates were highest in countries to 
which diphtheria is not endemic, where unfamiliarity can lead 
to delays in diagnosis and treatment. In western Europe, 
toxigenic Corynebacterium ulcerans has increasingly been 
identiﬁ   ed as the etiologic agent. Reduction in diphtheria 
incidence over the past 10 years is encouraging, but 
maintaining high vaccination coverage is essential to 
prevent indigenous C. ulcerans infections and reemergence 
of C. diphtheriae.
I
n 1994, following success of widespread vaccination 
programs earlier in the century, diphtheria was 
proposed as a candidate for elimination in the World 
Health Organization (WHO) European Region; the goal 
was for elimination of indigenous diphtheria by 2000 (1). 
However, during the 1990s, when this goal seemed within 
sight, several factors caused a resurgence of diphtheria to 
epidemic proportions in the newly independent states of 
the former Soviet Union. There were a large number of 
unnecessary contraindications to vaccination in guidance 
for these countries at that time, which led to reductions in 
adequate vaccination coverage in children. This problem 
was exacerbated by mistrust in vaccinations among health 
professionals and the public and by use of low-dose 
formulation vaccine for primary vaccinations. Waning 
immunity in the adult population, large-scale population 
movements caused by breakup of the former Soviet Union, 
disruptions in health services, and lack of adequate supplies 
of vaccine and antitoxin for prevention and treatment in 
most affected countries provided conditions under which 
diphtheria could spread (2,3). At the peak of the epidemic 
in 1995, there were >50,000 cases reported in the WHO 
European Region (2). Intensive vaccination strategies 
brought the disease under control in most countries, but 
some endemic transmission still continues.
Clinical diphtheria is caused by toxin-producing 
corynebacteria. Three species (Corynebacterium 
diphtheriae,  C. ulcerans, and C. pseudotuberculosis) 
can potentially produce diphtheria toxin. C.  diphtheriae 
is the most common of potentially toxigenic species and 
is associated with epidemic diphtheria and person-to-
person spread. The organism has 4 biovars (gravis, mitis, 
intermedius, and belfanti). C.  ulcerans is historically 
associated with cattle or raw dairy products, and, although 
it is rarely reported, its incidence has increased slightly in 
some countries in western Europe and in the United States 
in recent years (4–6). C. pseudotuberculosis rarely infects 
humans and is typically associated with farm animals (7). 
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Currently, no direct evidence has been found of person-to-
person spread of C. ulcerans or C. pseudotuberculosis.
Classical respiratory diphtheria is characterized by 
formation of a gray-white pseudomembrane in the throat 
that is ﬁ  rmly adherent (8). A swollen, bull-neck appearance 
caused by inﬂ   ammation and edema of soft tissues 
surrounding lymph nodes is associated with severe illness 
and higher death rates (8). In progressive disease, the toxin 
can bind to cardiac and nerve receptors and cause systemic 
complications. Milder respiratory disease may manifest as 
a sore throat, most commonly seen in patients who are fully 
or partially vaccinated. In some tropical areas, cutaneous 
symptoms, characterized by rolled-edge ulcers, are more 
common. Patients may have both cutaneous and respiratory 
disease. The purpose of this study was to analyze diphtheria 
data for Europe during 2000–2009.
Methods
Case-based diphtheria surveillance data from each of 
25 Diphtheria Surveillance Network (DIPNET) member 
countries (Austria, Belgium, Bulgaria, Cyprus, Czech 
Republic, Denmark, Estonia, Finland, France, Germany, 
Greece, Ireland, Italy, Latvia, Lithuania, the Netherlands, 
Norway, Poland, Portugal, Romania, Slovenia, Spain, 
Sweden, Turkey, and the United Kingdom) for 2000–2007 
were submitted retrospectively to the coordinating center 
in the United Kingdom during 2008. Data for 2008 and 
2009 were obtained in August 2009 and September 2010 
from the DIPNET online database, which was launched in 
September 2007.
We analyzed cases meeting the DIPNET case deﬁ  nition 
(isolation of a toxigenic strain or clinically compatible 
case with an epidemiologic link to a laboratory-conﬁ  rmed 
case) (online Technical Appendix 2, wwwnc.cdc.gov/
EID/pdfs/11-0987-Techapp2.pdf). In addition, 48 cases 
without laboratory conﬁ   rmation and pseudomembrane 
(mild diphtheria/severe pharyngitis) and 5 cases with 
unknown manifestations were included for Latvia because 
these cases had been recorded in the national dataset. For 
most cases, toxigenicity was conﬁ  rmed by using the Elek 
phenotypic test (9). However, in some cases, toxigenicity 
was evaluated only by detection of the toxin gene with PCR. 
We assumed that all cases in this dataset were toxigenic 
(toxin producing) because the number of cases without Elek 
conﬁ  rmation was small and referred to symptomatic cases. 
Data ﬁ  elds collected included year; organism; biovar; and 
patient age, sex, clinical manifestations, vaccination status, 
veterinary contact, risk group, and outcome. Further strain 
characterization (ribotyping) was available for a limited 
number of isolates as part of a screening study in 10 
DIPNET countries (10).
Cases were assigned to 5 clinical manifestation groups. 
These groups were classic respiratory diphtheria with 
pseudomembrane (the most serious form of the disease); 
mild diphtheria/severe pharyngitis (respiratory symptoms 
without the pseudomembrane); cutaneous (toxigenic 
organism isolated from skin lesions); other (e.g., toxigenic 
organism isolated from blood); and asymptomatic (carriers 
of toxigenic organisms, usually contacts of a conﬁ  rmed 
case-patient).
Additional information concerning countries in the 
WHO European Region that are not DIPNET member 
countries was provided by the WHO Regional Ofﬁ  ce for 
Europe. Twenty-ﬁ   ve of 53 member states of the WHO 
European Region are members of DIPNET. WHO European 
Region countries (including DIPNET members) report total 
cases annually to the WHO Regional Ofﬁ  ce  for  Europe 
through the WHO/United Nations Children’s Fund Joint 
Reporting Form, which is the global annual data survey of 
WHO member states for vaccine-preventable diseases and 
immunization program indicators. In addition, 16 countries 
in 2003 (Figure 1) were asked to prospectively participate in 
monthly surveillance and provide more detailed information 
(e.g., pathogen biovar; patient age, sex, and outcome; 
and carriers among contacts). Twelve countries currently 
provide monthly reports to WHO Regional Ofﬁ  ce  for 
Europe through this system. The only major source of cases 
that has not participated in the monthly reporting system (but 
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Figure 1. Diphtheria Surveillance Network (DIPNET) and World 
Health Organization (WHO) European Region countries. 1, Albania; 
2, Andorra; 3, Armenia; 4, Austria; 5, Azerbaijan; 6, Belarus; 7, 
Belgium; 8, Bosnia and Herzegovina; 9, Bulgaria; 10, Croatia; 11, 
Cyprus; 12, Czech Republic; 13, Denmark; 14, Estonia; 15, Finland; 
16, France; 17, Georgia; 18, Germany; 19, Greece; 20, Hungary; 21, 
Iceland; 22, Ireland; 23, Israel (neighboring countries not shown); 
24, Italy, 25; Kazakhstan; 26, Kyrgyzstan; 27, Latvia; 28, Lithuania; 
29, Luxembourg; 30, Malta; 31, Monaco; 32, Montenegro; 33, the 
Netherlands; 34, Norway; 35, Poland; 36, Portugal; 37, Republic of 
Moldova; 38, Romania; 39, Russian Federation; 40, San Marino; 
41, Serbia; 42, Slovakia; 43, Slovenia; 44, Spain; 45, Sweden; 
46, Switzerland; 47, Tajikistan; 48, Former Yugoslav Republic of 
Macedonia; 49, Turkey; 50, Turkmenistan; 51, Ukraine; 52, United 
Kingdom (Great Britain and Northern Ireland); 53, Uzbekistan. Diphtheria in Europe, 2000–2009
does report annually) is the Russian Federation. Rates per 
1 million person-years were calculated by using population 
estimates derived from the Population Division of Economic 
and Social Affairs of the United Nations Secretariat (11).
Statistical Analyses
Proportions were compared by using χ2 or Fisher exact 
tests, as appropriate, in Stata statistical software version 7.0 
(StataCorp LP, College Station, TX, USA). For assessment 
of a trend for variables in ordered groups (vaccinated, 
partially vaccinated, unvaccinated) and severity of disease 
(classic respiratory, mild diphtheria/severe pharyngitis, 
asymptomatic), the Wilcoxon test for trend in Stata (12) 
was used. This test enabled nonparametric analysis across 
these groups.
Results
Overall, across the WHO European Region, the number 
of cases of diphtheria has substantially decreased since 
the epidemic in the 1990s (Figure 2). Data on clinically 
conﬁ  rmed cases and toxigenic isolates of C. diphtheriae 
and C. ulcerans reported to DIPNET during 2000–2009 are 
shown in Tables 1 and 2, respectively. Member countries 
that are not listed reported no isolates. Data are analyzed 
separately for Latvia, where diphtheria is endemic.
Diphtheria-Endemic Countries in 
WHO European Region
During 2000–2009, Latvia reported the highest annual 
incidence rate of diphtheria in the European Region each 
year and a 10-year incidence rate of 23.8 cases/1 million 
person-years. This rate was ≈7× higher than in countries 
with the next highest 10-year incidence: i.e., Georgia (3.5), 
Ukraine (3.3), and the Russian Federation (3.0). However, 
during this time, 4,304 (>61%) of 7,032 cases in the 
WHO European Region were reported from the Russian 
Federation, and 2 countries, the Russian Federation and 
Ukraine, accounted for 83% of all cases.
Over the past 10 years, diphtheria incidence decreased 
by >95% across the region (from 1.82/1 million population 
in 2000 to 0.07/million in 2009), including in Latvia (from 
111.22/million in 2000 to 2.67/million in 2009). In 2009, 
Latvia was the only country in the region that had not yet 
achieved the elimination benchmark of an incidence <1 
case/million population (Figure 2).
Most cases reported to WHO through the monthly 
surveillance system were in teenagers and adults. However, 
the major risk groups for death have been infants (too 
young for complete primary vaccination) and adults >40 
years of age (unvaccinated or with waning immunity). 
Although risk did not differ by sex in cases in children, 
during 2002–2009, ≈2× as many cases were reported in 
women >20 years of age than in men (510 [64%] vs. 292 
[36%], respectively). Most (75%) case-patients reported 
in the European Region were at least partially vaccinated, 
but most (74%) case-patients and (93%) infants who died 
were unvaccinated). C. diphtheriae biovar gravis was the 
predominant strain (60%–80%). Of isolates from Latvia 
(Table 1), 355 (99%) of 358 with a known biovar were 
gravis and 3 (1%) were mitis.
Clinical manifestations and vaccination status for 
cases from Latvia (all C. diphtheriae) reported to DIPNET 
are shown in Table 3. Most (340/341) case-patients with 
symptoms had respiratory manifestations, and 141 (41%) 
of 340 respiratory case-patients had classic diphtheria 
symptoms. Vaccination showed a signiﬁ  cant  protective 
effect with respect to severity of infection (p<0.001 by test 
for trend).
For symptomatic cases for 2002–2009 (excluding the 
military outbreak in 2000 and cases from 2001 for which 
limited information was available) the highest overall 
incidences were in children 0–4 and 5–15 years of age 
and adults 45–64 years of age; lower incidence rates were 
observed in other age groups (Figure 3). Most (123/196, 
63%) symptomatic cases during those years were in female 
patients.
The second most common risk factor (after military 
service) identiﬁ   ed among symptomatic case-patients in 
Latvia was unemployment (60 case-patients). Information 
was not available regarding connections of case-patients to 
other countries of the former Soviet Union.
Non–Disease-Endemic Countries (DIPNET)
Clinical manifestations and immunization status for 
case-patients with toxigenic C. diphtheriae and C. ulcerans 
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F    igure 2. Diphtheria cases per 1 million population in the World 
Health Organization (WHO) European Region and number of 
countries with a rate >1 cases/1 million population, 2000–2009.RESEARCH
isolates and epidemiologically linked cases reported by 
24 DIPNET member countries, excluding Latvia, during 
2000–2009 are shown in Table 4. Vaccination had a 
signiﬁ   cant protective effect with respect to severity of 
infection (p = 0.001 by test for trend).
C. diphtheriae Isolates
Isolates of C. diphtheriae were sporadically reported 
in the 24 DIPNET member countries, excluding Latvia. 
Each year, 0–6 symptomatic cases of toxigenic C. 
diphtheriae infection were reported by each country (53 
cases during 2000–2009). For each case-patient, 0–4 
asymptomatic contacts were reported (14 in the 10-year 
period). Of 60 isolates with a biovar recorded during 
2000–2009, a total of 32 were gravis and 28 were mitis. 
Seventeen cutaneous cases, 35 respiratory (24 classic 
respiratory) cases, and 1 case with other manifestations 
were reported. Most (15/17, 88%) cutaneous cases were 
caused by biovar mitis, and most (17/28, 61%) respiratory 
cases with a known biovar were caused by biovar gravis. 
Sixteen of 17 patients with cutaneous disease had recently 
returned from traveling, had contact with travelers, or were 
recent immigrants from a disease-endemic area, as was 
the situation for 12 of 35 patients with respiratory disease. 
One case-patient with bacterial endocarditis had contact 
with a relative who had recently traveled to Pakistan. For 
case-patients with C. diphtheriae symptomatic infection, 
sex distribution was even. A higher incidence rate was 
observed in male patients 0–4 years of age (Figure 3), but 
this ﬁ  nding was inﬂ  uenced by 6 cases reported in Turkey 
during 2001–2003.
C. ulcerans Isolates
A total of 4–8 isolations of toxigenic C. ulcerans were 
reported by DIPNET member countries each year (53 [50 
symptomatic] during 2000–2009). Of these cases, 51% 
were reported by the United Kingdom, 19% by Germany, 
and 17% by France. Of the symptomatic cases for which 
patient sex/age group were known, 38 (78%) of 49 were 
in female patients and 29 (59%) of 49 were in patients >45 
years of age. Incidence rate was higher in female patients 
than in than male patients (0.014/1 million person-years vs. 
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Table 1. Toxigenic Cornyebacterium diphtheriae isolates and epidemiologically linked cases and deaths reported by DIPNET member 
countries, Europe, 2000–2009* 
Characteristic
Patient
description†
No. toxigenic isolates or clinical cases with epidemiologic link (no. deaths) 
2000  2001 2002 2003 2004 2005 2006 2007 2008 2009 
Country               
  Estonia  Symptomatic 2  2 0 0 0 0 0 0 0 0 
Asymptomatic  1  7 0 0 0 0 0 0 0 0 
Total  3  9 0 0 0 0 0 0 0 0 
  Finland  Total  0  2  (1)  0 0 0 0 0 0 0 0 
  France  Total  0  0 1 0 1 0 1  1  (1)  1 0 
  Germany  Total  1  2 4 0 0 1 0 0 0 2 
  Latvia  Symptomatic 145  0  45 26 20 20 32 18 29  6 
Asymptomatic  61 24  15  22 2  2 11 5 12 3 
Not  known 119  91  0 0 0 0 0 0 0 0 
Total  325 (9)  115 (5) 60 (3)  48 (2)  22 (1)  22 (2)  43 (6)  23 (1)  41 (2)  9 (1) 
  Lithuania  Symptomatic 2  0 4 0 0 0 0 0 2 0 
Asymptomatic  0  0 1 0 0 0 0 0 2 0 
Total  2  0  5  (1)  0 0 0 0 0  4  (1)  0 
  Norway  Symptomatic 0  0 0 0 0 0 0 0 3 0 
Asymptomatic  0  0 0 0 0 0 0 0 1 0 
Total  0  0 0 0 0 0 0 0 4 0 
  Sweden  Total  0  0 0 0 0 0 0 0 0 1 
  Turkey  Symptomatic 1  3 1 0 0 0 0 0 0 0 
Asymptomatic  2  0 0 0 0 0 0 0 0 0 
Not  known  1  4 1 1 0 0 0 0 0 0 
Total  4 (1)  7 (3)  2 (1)  1  0  0  0  0  0  0 
  United  Kingdom  Total  1  0 6 3 0 0 1 0  2  (1)  2 
Total known symptomatic 
patients
NA  152  9  61 29 21 21 34 19 37 11 
Total (all countries)  NA  336 (10) 135 (9) 78 (5)  52 (2)  23 (1)  23 (2)  45 (6)  24 (2)  52 (4)  14 (1) 
Total known symptomatic 
patients, excluding Latvia 
NA  7  9  16  3 1 1 2 1 8 5 
Total, excluding Latvia  NA  11 (1)  20 (4)  18 (2)  4  1  1  2  1 (1)  11 (2)  5 
*DIPNET, Diphtheria Surveillance Network; NA, not applicable. A total of 89 cases were clinically diagnosed without microbiological confirmation (76 in 
Latvia, 11 in Turkey, and 2 in Lithuania). 
†If only total is displayed for a country, all patients were symptomatic. Diphtheria in Europe, 2000–2009
0.004/1 million person-years). Eleven cutaneous cases, 38 
respiratory (14 classic respiratory) cases, and 1 case with 
other manifestations were reported. Ninety-four percent 
of case-patients for which information was available had 
contact with domestic animals. Traditional risk factors such 
as consumption of raw milk products were not reported, 
and no patients had a recent history of travel. One of the 
2 case-patients infected with C. ulcerans who died in the 
United Kingdom had an identical strain of C. ulcerans to 
that isolated from a dog with which the patient had been 
in contact (14). A similar ﬁ  nding was observed in France 
for a nontoxigenic case reported in 2003 (5,15). In 2007, 
identical strains were isolated from a patient infected with 
C. ulcerans and her pig in Germany (16).
C. pseudotuberculosis Isolates
Four case-patients with diphtheria caused by toxigenic 
C. pseudotuberculosis were reported: 1 in France in 2005 
and 1 in 2008, 1 in Germany in 2004, and 1 in United 
Kingdom in 2008. Three of these patients had cutaneous 
manifestations (1 was unvaccinated, 2 had an unknown 
vaccination status) and 1 (partially vaccinated) had bacterial 
endocarditis. To our knowledge, none of these infected 
patients died. Animal contact (with a calf) was recorded for 
only 1 patient (1 had no history of animal contact and 2 had 
an unknown history of animal contact).
Deaths Caused by Diphtheria
During 2000–2009, a total of 32 deaths caused by 
diphtheria were reported in Latvia, and 13 deaths (10 
caused by C. diphtheriae and 3 caused by C. ulcerans) 
(Tables 1, 2) were reported by the remaining 24 DIPNET 
countries. Overall, patients with respiratory disease and a 
pseudomembrane had a signiﬁ  cantly higher case-fatality 
rate (CFR) than patients with respiratory disease without 
a pseudomembrane (14.6% vs. 1.3%; p<0.001). For case-
patients in Latvia, the CFR was 5% for patients with any 
respiratory symptom (including classic manifestations) and 
12% for patients with classic respiratory symptoms. Of 18 
case-patients in Latvia who died, 14 were >40 years of age 
and 4 were <7 years of age; all were unvaccinated.
Nine of 13 patients who died of diphtheria in DIPNET 
countries excluding Latvia had classic respiratory diphtheria 
symptoms, and 2 had severe pharyngitis (2 had unknown 
manifestations). All 3 deaths caused by C. ulcerans (2 in 
the United Kingdom and 1 in Germany) were in elderly 
(>75 years of age) patients (unvaccinated or vaccination 
status unknown). Two of the patients infected with C. 
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Table 2. Isolates of toxigenic Corynebacterium ulcerans and patient deaths reported by DIPNET member countries, Europe, 2000–
2009*
Characteristic
Patient
description†
No. toxigenic isolates (no. deaths) 
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 
C o u n t r y               
  France  Total  0 1 0 1 3 0 2 1 0 1 
  Germany  Total  1  1  (1)  0 0 1 2 1 2 0 2 
  Italy  Total  0 0 1 0 0 0 0 0 0 0 
  The  Netherlands  Total  0 1 0 0 0 0 0 1 0 0 
  Romania  Asymptomatic  0 0 1 0 0 0 0 0 0 0 
Total  0 0 1 0 0 0 0 0 0 0 
  Sweden  Symptomatic  0 0 0 0 0 0 0 0 1 0 
Not  known 0 0 0 0 1 0 1 0 0 0 
Total  0 0 0 0 1 0 1 0 1 0 
  United  Kingdom  Total  7  (1)  3 2 2 1 2  2  (1)  3 3 2 
No.  symptomatic  patients  NA  8 6 3 3 5 4 5 7 4 5 
No. isolates  NA  8 (1)  6 (1)  4  3  6  4  6 (1)  7  4  5 
*DIPNET, Diphtheria Surveillance Network; NA, not applicable 
†If only total is shown for a country, all patients were symptomatic. 
Table 3. Vaccination status of case-patients and clinical manifestations of toxigenic Corynebacterium diphtheriae infections and 
epidemiologically linked cases without laboratory confirmation, Latvia, Europe, 2000–2009* 
Vaccination status 
Classic diphtheria 
(with membrane) 
Mild diphtheria/ 
severe pharyngitis  Cutaneous Asymptomatic  Not  known Total 
Full 64†  118  0  71  0  253 
Partial 1  3  0  5  0  9 
Unvaccinated 74  70  1  18  0  163 
Not known  2  8  0  63  210  283 
Total 141  199  1  157  210  708 
*p<0.001 by test for trend (vaccination status and disease severity). 
†Includes 52 fully vaccinated case-patients with classic respiratory diphtheria (with membrane) from an outbreak in the military in 2000. The outbreak 
comprised 145 symptomatic case-patients and 25 asymptomatic contacts. A total of 96% of these case-patients and contacts were 18–23 years of age at 
the time of diagnosis. Spread of disease was traced to use of a communal drinking cup (13).RESEARCH
diphtheriae who died were unvaccinated infants (1 from 
Mayotte and 1 from Finland). The infant in Finland died at 
3 months of age in 2001 after recent contact with visitors 
from Russia (17). Six other children died: an unvaccinated 
school age child in the United Kingdom (18) and 5 children 
<7 years of age in Turkey (vaccination status unknown). 
Two adults in Lithuania (ages 45–64 years; vaccination 
status unknown) also died. The CFR for patients with any 
respiratory symptoms reported for patients infected with 
toxigenic C. diphtheriae or C. ulcerans in regions where 
diphtheria was not endemic was 15%; CFR was 24% 
among patients with classic respiratory diphtheria.
The difference between CFRs for respiratory diphtheria 
cases in Latvia and member countries excluding Latvia (5% 
and 15%, respectively) was signiﬁ  cant (p = 0.002). The 
difference between CFRs for classic respiratory diphtheria 
in Latvia and the member countries excluding Latvia (12% 
and 24%, respectively) showed borderline signiﬁ  cance (p 
= 0.06).
Any case-patients without symptoms recorded who 
died likely had respiratory diphtheria. However, because 
symptoms were also not available for several surviving 
case-patients for whom clinical manifestations were less 
certain, all case-patients for whom clinical manifestations 
were unavailable were excluded from analysis.
Discussion
Substantial progress has been made in controlling 
diphtheria across Europe since the epidemic in the 1990s, 
but diphtheria has not disappeared as a serious public 
health threat. After major disruption to a mass vaccination 
program, recovery time is lengthy, and pockets of 
unvaccinated persons can remain because recovery is not 
necessarily homogeneous.
The protective effect of vaccination in preventing 
progression to severe disease is clear. However, 64 patients 
in Latvia recorded as fully vaccinated had classic respiratory 
diphtheria symptoms. Most of these patients were infected 
during a military outbreak in 2000 and would have been 
scheduled for primary vaccinations during the 1980s, when 
changes in vaccines, vaccination policy, medical practice, 
and public acceptance led to less intensive vaccination of 
children in the former Soviet Union. Beginning in 1980, 
Soviet vaccination recommendations enabled use of an 
alternative primary vaccination schedule against diphtheria 
that recommended 3 doses of a lower-potency vaccine (19). 
The classiﬁ   cation of fully/partially vaccinated relies on 
speciﬁ  c interpretation of a country. Since the 2000 outbreak, 
greater attention has been given to checking vaccination 
records of new recruits into the Latvian military, and 
booster vaccinations are given where appropriate.
Lower CFRs for respiratory diphtheria in disease-
endemic areas compared with those in nonendemic areas 
highlight how lack of familiarity with a rare disease 
can affect diagnosis and treatment. As the incidence 
of diphtheria has decreased, so has the practice of 
routine laboratory screening (20). No DIPNET member 
country routinely screens all throat swab specimens for 
corynebacteria, although sentinel screening of all throat 
swab specimens is conducted in Denmark, Ireland, and 
the United Kingdom. All other DIPNET countries (and 
outside sentinel screening areas) perform screening 
only at the request of the clinician or if the laboratory 
identiﬁ  es particular criteria for screening from information 
accompanying a swab specimen (DIPNET, unpub. data). 
This practice has resulted in a loss of laboratory expertise 
and the opportunity for infections to go undetected because 
only clinically indicated swab specimens are tested; thus, 
milder cases or those with unusual manifestations may be 
missed.
A recent DIPNET external quality assurance 
evaluation of 6 simulated throat specimens found that only 
6 of 34 international centers produced acceptable results 
for all 6 specimens; many centers could not isolate the 
target organism (21). In some poor countries, screening 
can be limited by cost of laboratory reagents, and problems 
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Figure 3. Diphtheria incidence per 1 million person-years for Latvia 
(Corynebacterium diphtheriae, 2002–2009) and the remaining 
24 Diphtheria Surveillance Network (DIPNET) countries (C. 
diphtheriae and C. ulcerans, 2000–2009). Error bars indicate 95% 
CIs. The period 2002–2009 excludes the military outbreak in 2000 
and cases from 2001 for which limited information was available.Diphtheria in Europe, 2000–2009
have also occurred in obtaining Elek reagents and media 
(21). During a recent screening study across 10 countries 
in Europe, toxigenic organisms were isolated in Latvia 
and Lithuania (10). At least one of these cases in Lithuania 
would not have been correctly diagnosed in the absence 
of the screening study. In addition to the potential for 
missed or late diagnoses, in areas where diphtheria is 
not endemic, diphtheria antitoxin treatment is not always 
available, which can have serious consequences. A recent 
international survey highlighted global shortages of 
diphtheria antitoxin (22). Information about administration 
and timing of antitoxin treatment was not collected for this 
analysis, but studying such timing in relation to differing 
CFRs would be useful.
Higher incidence rates of C. diphtheriae among women 
in disease-endemic countries could be caused by several 
factors. Women more commonly work as caregivers in 
domestic and health care settings, consultation rates are 
usually higher among women, and men are more likely to 
have received diphtheria vaccine during military service.
Although the United Kingdom, France, and Germany 
regularly report isolations of toxigenic C. ulcerans, it 
is unlikely that this organism is present only in these 
countries. The ability to detect C. ulcerans could indicate 
the capability of a country to detect potentially toxigenic 
organisms and provide an indicator of good surveillance. 
Detection of mild diphtheria cases (any toxigenic organism) 
is another potential indicator of good surveillance. C. 
ulcerans appears to have a wide host range and has been 
isolated from many domestic and wild animals, including 
the killer whale and lion (nontoxigenic strain) (23). During 
2002 and 2003, toxigenic C. ulcerans strains isolated from 
domestic cats in the United Kingdom were found to have 
the predominant ribotypes observed among human clinical 
isolates, which suggests that cats could be a potential 
reservoir for human infection (24). Identical C. ulcerans 
strains have been isolated from diphtheria patients and 
dogs in France and the United Kingdom (14,15). The 
presence of this organism reinforces the need to maintain 
high vaccination levels in all countries. Higher incidence 
of infection among elderly women could be related to 
pet ownership habits, in combination with low or waning 
immunity.
Vaccination coverage for diphtheria is assessed 
annually in many countries in Europe by using a 
range of methods, including computerized vaccination 
registers, survey methods, administrative methods, or a 
combination (25). These methods will provide varying 
degrees of accuracy in coverage estimates, which makes 
countries difﬁ  cult to compare. Coverage for vaccination 
with diphtheria-tetanus-pertussis 3 vaccine (third dose of 
diphtheria, tetanus, pertussis vaccine) in early childhood in 
2009 was >90% for most (85%) countries in the European 
Region, and 66% of countries (including Latvia, Lithuania, 
Turkmenistan, and the Russian Federation) reported 
coverage >95% (26). Coverage in Ukraine decreased from 
98% in 2006 and 2007 to 90% in 2008 and 2009. Austria, 
Denmark, Georgia, and Moldova recorded diphtheria-
tetanus-pertussis 3 vaccine coverage <90%. Azerbaijan and 
Malta had the lowest coverage (73% for both countries) in 
the European Region in 2009.
Following high-proﬁ   le vaccine-scare stories in 
some countries in eastern Europe, such as the Russian 
Federation and Ukraine, anti-vaccination groups have 
gained strength by using television, the Internet, and other 
media for publicity (27); this activity could seriously 
affect vaccination coverage. Adult diphtheria immunity 
can be increased through scheduled booster vaccinations 
every 10 years (e.g., as in Austria, Belgium, Bulgaria, 
Cyprus, Estonia, Finland, France, Germany, Greece, 
Latvia, Norway, Portugal, and Romania) or as part of 
a combined tetanus and low-dose diphtheria vaccine 
given for tetanus-prone injuries. In Latvia, annual adult 
vaccination coverage surveys are undertaken, but in most 
countries adult coverage is rarely assessed. Seroprevalence 
studies have indicated that many adults in some countries 
have immunity levels below the protective threshold (28). 
Gaps in immunity in the adult population contributed to 
the resurgence of diphtheria in eastern Europe during the 
1990s.
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Table 4. Vaccination status of case-patients and clinical manifestations of toxigenic Corynebacterium diphtheriae and C. ulcerans
infections and epidemiologically linked cases without laboratory confirmation, DIPNET cases excluding Latvia, Europe, 2000–2009*
Vaccination status 
Classic respiratory 
diphtheria (with 
membrane) 
Mild respiratory 
diphtheria/severe 
pharyngitis Cutaneous  Other  Asymptomatic  Not  known Total 
Full 4  17  2  1†  2  0  26 
Partial 5  3  7  0  0  0  15 
Unvaccinated 14  3  4  0  1  0  22 
Not known  15  10  15‡  1§  12  11¶  64 
Total  38  33  28  2 15 11  127 
*DIPNET, Diphtheria Surveillance Network. p = 0.001 by test for trend (vaccination status and disease severity). 
†Bacterial endocarditis (C. diphtheriae, fully vaccinated) 
‡One cutaneous case-patient also had a sore throat. 
§Isolation from blood (C. ulcerans, vaccination status not known). 
¶Includes 2 case-patients infected with C. diphtheriae who died and are assumed to have respiratory symptoms without specific details available. RESEARCH
Trends in diphtheria cases in Europe are encouraging, 
but continued striving for improved vaccination coverage 
is essential. Diphtheria has a socioeconomic component; 
outbreaks are typically seen in marginalized groups. In the 
current economic climate, more socially deprived groups 
that are vulnerable to infection will emerge. The economic 
crisis may also threaten supplies of vaccine and antitoxin and 
delivery of immunization programs. Because reductions in 
ﬁ  nances can limit the capacity for surveillance, decreases 
in case reporting need to be interpreted with caution. Every 
effort must be made to maintain high diphtheria vaccination 
coverage.
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